Thank you
Thank you for joining our webinar today sponsored by Bayer. Industry Innovations Webinars are archived on the ATS YouTube channel.
Description
Managing adult PAH (WHO Group 1) patients at intermediate
risk. A look at REPLACE: Phase IV Study data.
Please join us for an exciting webinar releasing data from
the Phase IV REPLACE (Riociguat rEplacing PDE-5i therapy evaLuated
Against Continued PDE-5i thErapy) study.
The REPLACE study was a prospective, randomized, controlled,
open label, international, multicenter study evaluating the efficacy of Adempas
in adult patients with pulmonary arterial hypertension (PAH) (WHO Group 1) who
are receiving a stable dose of a PDE5i and still at intermediate risk.
Adempas is indicated for the treatment of
adult patients with PAH to improve exercise capacity, improve WHO Functional
Class (FC), and delay clinical worsening.* Efficacy was shown in patients on
Adempas monotherapy or in combination with endothelin receptor antagonists
(ERA) or prostanoids (PCA). Studies establishing effectiveness included
predominantly patients with WHO FC II–III.
* Time to clinical worsening was a combined endpoint defined as death (all-cause mortality), heart/lung transplantation, atrial septostomy, hospitalization due to persistent worsening of pulmonary hypertension, start of a new PAH-specific treatment, persistent decrease in 6MWD, and persistent worsening of WHO functional class.
This program is sponsored by Bayer.
By registering for this
webinar, you agree your information will be shared with the sponsor.
No CME or MOC credits are
available for this program.
Opinions expressed and
resources shared may not have been reviewed by the ATS prior to distribution
through ATS channels, or reflect official positions of the ATS, unless it is
explicitly noted as a result of official ATS approval. References to specific commercial
entities (companies) or products do not reflect review or endorsement by the
ATS unless it is explicitly noted as a result of official ATS approval.